Abstract Gout affects 8.3 million Americans according to NHANES 2007NHANES -2008, approximately 3.9 % of the US population. Gout has substantial effect on physical function, productivity, health-related quality of life (HRQOL), and health care costs. Uncontrolled gout is also associated with significant use of emergency care services. Women are less likely to have gout than men, but in the postmenopausal years the gender difference in disease incidence decreases. Compared with whites, racial and/or ethnic minorities, especially blacks, have higher prevalence of gout. Blacks are also less likely to receive quality gout care, leading to disproportionate morbidity. Women are less likely than men to receive allopurinol, and less likely to undergo joint aspirations for crystal analysis to establish diagnosis, but those on urate-lowering therapy are as likely as, or more likely than, men to undergo serum urate check within six months of initiation. Although a few studies provide the knowledge related to gender and race and/or ethnicity disparities for gout, several knowledge gaps exist in gout epidemiology and outcomes differences by gender and race and/or ethnicity. These should be investigated in future studies.
report, the committee made three recommendations with respect to data collection and monitoring:
1. collection and reporting of data on health care access and utilization by patient's race, ethnicity, socioeconomic status, and, where possible, language; 2. inclusion of measures of racial and ethnic disparities in assessing provider performance; and 3. monitoring of progress toward the elimination of health care disparities [29, 30] .
Subsequently, the 2009 IOM's comparative effectiveness research (CER) agenda listed "Comparison of effectiveness of literacy-sensitive disease management programs and usual care in reducing disparities in children and adults with low literacy and chronic disease" in the first quartile of the 100 top-priority areas [31] . As in the 2002 report, the 2009 agenda not only emphasized the importance of racial and/or ethnic disparities in health care, but also emphasized the challenge of knowledge gaps in implementation of research intended to reduce disparities. By identifying barriers to quality health care, high-quality research can lead to the identification of targets for intervention and thus improve the overall quality of care for racial and/or ethnic minorities. The Affordable Care Act (ACA) recognized minority health as a priority by establishing minority health offices [32] . The Agency for Healthcare Research and Quality (AHRQ) similarly recognized the importance of minority health disparities through its issuance of Special Emphasis Notices [33] .
Gender disparities in health care have also been widely reported [34] [35] [36] [37] [38] . The 2003 IOM report on Women's Health Research noted that the under-representation of women in many past studies limits the generalizability of their findings [39] . Women's health is a priority area for AHRQ, and two key publications from the agency, the National Healthcare Quality Report (NHQR) and the National Healthcare Disparities Report (NHDR), emphasized its importance. NHDR focused on "prevailing disparities in health care delivery as it relates to racial factors and socioeconomic factors in priority populations"; priority populations include racial and ethnic minorities, and women, among others [40] . The Affordable Care Act (ACA) also recognized women's health as a priority by establishing women's health offices [32] .
In this review, we summarize the evidence regarding racial and/or ethnic and gender disparities in gout, and identify areas for further research including the types of studies needed to identify and close gaps in care of minorities and women with gout.
The Burden of Gout as a Musculoskeletal Disorder
Gout is a prototypical inflammatory arthritis, similar in many ways to rheumatoid arthritis (RA). However, in contrast with RA, which is primarily driven by autoimmunity, gout is a metabolic disease characterized by the effects of hyperuricemia on the joints, kidneys, and other systems. According to recent studies, gout prevalence is estimated at 4 % in the US [41••] , which is at least four-times that of RA, its closest rival [42] . Gout has a significant effect on patient's lives and on their function [43] , productivity [44, 45] , and health-related quality of life (HRQOL) [43, 46, 47] .
Recent studies have also revealed gout is an independent risk factor for cardiovascular morbidity and mortality, making treatment of gout relevant not only for the rheumatologist and the nephrologist, but also for the internist and the cardiologist. Gout is an independent risk factor for myocardial infarction (MI) in men [48] and women [49••] . After adjustment for traditional risk factors, use of diuretics and aspirin, and serum creatinine level, patients with gout were at 1.35-times greater risk of coronary heart disease mortality (95 % confidence interval [CI], 1.06-1.72) compared with those without gout [50] . Gout was also associated with an adjusted risk of 1.74 (95 % CI, 1.03-2.93) for incident heart failure and higher relative risk of 3.70 (95 % CI, 1.68-8.16) for abnormally low left ventricular ejection fraction [51••] . Gout was independently associated with a 1.5-fold increase in risk of mortality for dialysis patients, after adjusting for black race, older age, female gender, hypertension, ischemic heart disease, congestive heart failure, and alcohol use [52] . These studies emphasize that gout is a systemic disease, and provide support that its effect goes far beyond the joint and the musculoskeletal system.
Disparity in Epidemiology of Gout

Racial and/or Ethnic Differences in Prevalence
Genetic studies of African-Americans have found the same loci to be associated with hyperuricemia as those noted in European ancestry populations. Importantly, the most strongly associated locus for serum uric acid levels among European ancestry populations was also the most strongly associated locus in African-Americans [53•, 54] . Despite this sharing of hyperuricemia-related loci across racial and/ or ethnic groups, gout seems to be more prevalent in minorities. Several studies have provided evidence for disparities in the prevalence and incidence of gout by race and/or ethnicity.
In a recent study based on the US National Health and Nutrition Examination Survey (NHANES) conducted in 2007 and 2008, 3.9 % of the US population reported physician-diagnosed prevalent gout [41••] . Compared with whites, whose gout prevalence was 4.0 % (95 % CI, 3.3-4.8 %), the prevalence of gout was higher in blacks at 5.0 % (95 % CI, 3.3-6.6 %). This observation mirrored the higher prevalence of hyperuricemia in blacks than in whites, 25 In a different cohort study, the incidence of gout was 3.11 versus 1.82 per 1,000 person-years among black and white males, respectively [55] . This resulted in a relative risk of 1.69 (95 % CI, 1.02-2.80) in blacks versus whites. Incident hypertension was independently associated with the development of gout in black males in univariate analysis, and when this variable was included as a time-dependent covariate in a Cox model, the excess risk of gout among black males was reduced and no longer statistically significant (adjusted RR01.30; 95 % CI 0.77-2.19) [55] . These data suggest that at least some of the difference in gout risk among black males derives from related co-morbidities.
In contrast, in a study from the Atherosclerosis Risk in Communities (ARIC) study, a population-based bi-racial cohort comprising individuals aged 45-65 years at baseline (1987) (1988) (1989) , the graded association between BMI and incident gout (each P for trend <0.001) did not differ significantly between black and white females [56] . Similarly, the association of weight gain with incident gout also did not differ significantly between black and white women [56] .
In a recent study of gout among Hmong Chinese from the state of Minnesota, the prevalence of self-reported gout among Hmong was reported to be twofold higher than in the general US population as identified in NHANES III (6.5 % versus 2.9 %; P<0.001) [57] . Although women in both groups (Hmong Chinese and US general population) reported similar gout prevalence of 1.9 %, Hmong men were significantly more likely than their non-Hmong counterparts to report gout (11.5 % versus 4.1 %; P<0.001) [57] . In another study comparing Hmong in Minnesota to the general white population, the authors found that in a multivariable analysis (adjusted for age, sex, hypertension, diuretic use, and kidney disease), Hmong ethnicity was significantly associated with risk of tophaceous gout, with an odds ratio of 4.3 (95 % CI: 1.5, 12.2) [58] . This was despite the fact that Hmong Chinese immigrants had lower prevalence of diabetes mellitus, coronary vascular disease, and hyperlipidemia than whites at initial presentation.
A higher prevalence of hyperuricemia and gout has also been noted in the New Zealand Maori population, with half the Polynesian population of New Zealand having hyperuricemia, on the basis of European and North American standards [59] . Ten percent of New Zealand Maori males older than 20 years had gout. The Maoris also had higher prevalence of obesity, diabetes mellitus, hypertension, and associated degenerative vascular disorders, these being not only diseases associated with higher mortality but also risk factors for gout [59] . In a study comparing Maori and European students aged 13 to 16 years, Maori boys had a mean serum urate that was 1 mg/dl higher than that of European boys, and serum urate level among Maori girls was a mean of 0.5 mg/dl higher than among their European female counterparts [60] .
In summary, these studies indicate that some racial and/or ethnic groups had higher prevalence of gout than whites of European Ancestry. This was especially true for blacks and the Hmong Chinese in the US and New Zealand Maoris. Blacks in US and Maoris in New Zealand had higher prevalence of specific risk factors for gout (hypertension, obesity etc.), which partially, but not totally, explain the difference in prevalence. On the other hand Hmong Chinese immigrants to the US had lower prevalence of most gout risk factors, indicating that genetic factors and/or diet may underlie these differences.
Racial and/or Ethnic Differences in Clinical and Genetic Risk Factors for Gout
In another analysis of the US NHANES cohorts of 1988-1994 and 2007-2010, a linear trend of increasing prevalence of gout was seen for increasing body mass index (BMI), prevalence increasing from 1-2 % for subjects with normal BMI 18.5-24.9 to 7 % for those with BMI ≥35 kg/m 2 [61••] . Obesity, defined as BMI >30 kg/m 2 , was significantly associated with approximately twice the prevalence of gout, even after adjusting for serum uric acid and other comorbidities. In further analysis of the association of obesity with gout, prevalence by race and/or ethnicity, obesity among non-Hispanic whites was associated with 1.6-fold increased gout prevalence compared with non-obese; the respective prevalence ratio was 2.2-times in non-Hispanic blacks. This was indicative of a slightly greater risk of gout with obesity in the racial and/or ethnic minorities than in whites.
A New Zealand study reported that association of the ABCG2 gene (rs2231142 allele) with susceptibility to gout varied according to race and ethnicity [62] . Association of the minor allele of rs2231142 with gout was observed in the Pacific Islanders (odds ratio, OR02.80, P<0.001), but not in the Maoris (OR01.08, P00.70), with heterogeneity in association evident between the Maori and Pacific Island residents (P00.001) [62] . Similarly, rs2231142 was associated with risk of gout in people of western (Tonga, Samoa, Niue, Tokelau; OR02.59, P<0.001) but not eastern (Maori, Cook Island; OR01.12, P 00.48) Polynesian origin. An association of rs2231142 with gout was observed in the Caucasian samples, with an OR02.20 (P<0.00001). Thus, unlike SLC2A9, which is a strong risk factor for gout in both Maori and Pacific Island people, ABCG2 rs2231142 had a strong effect only in people of western Polynesian ancestry [62] .
Gender Differences in the Prevalence of Gout
Because women are protected against gout in the premenopausal period by the uricosuric effect of female sex hormones, men outnumber women in all age groups for gout prevalence, more in the younger than older age groups by a ratio of 5:1 to 10:1. Previous studies have reported gender differences in the prevalence of gout. In an analysis of the Framingham study, 2,283 men and 2,844 women aged 30-59, free from CHD at initial examination were analyzed [63] . Hall et al. reported that the prevalence of one or more attacks of gouty arthritis over a 12-year period was reported by 1.5 % overall, 2.8 % men and 0.4 % women [63] .
In a population-based study comparing the incidence of gout in Olmsted County, Minnesota, USA, the annual incidence of gout increased from 45.0/100,000 (95 % CI: 30.7, 59.3) in 1977-78 to 62.3/100,000 (95 % CI: 48.4, 76.2) in 1995-96, and doubling of the incidence of gout in two decades [64] . Gender differences were noted. The overall male-to-female ratio remained the same at 3.3 to 1 for both incidence cohorts. The incidence of gout increased with age in women and men, peaking in those 80 years and over.
In a study of 374,832 patients in 45 practices in England, Scotland, and Wales during 1971-75, gout incidence was reported at 0.3 per 1,000 per year. Age and gender data were available for 258,091. The prevalence of gout was higher in men at 6.1/1,000 men, compared with 1.0/1,000 women [65] . Among the different age strata, the prevalence (per 1,000) differed between men and women also, but the gap narrowed with increasing age: age 15-44, 1.7 vs. 0.1; age 45-64, 10.6 vs. 1.3; and age ≥65, 12.2 vs. 3.0 (Fig. 1a) [65] .
In a separate study of 40 practices in the UK including 300,000 patients, 2,865 were diagnosed with gout, i.e. overall prevalence of 9.5 per 1,000 patients [66] . In that study, gout prevalence in men was 16.4/1,000 compared with 2.93/1,000 in women. Analyzed according to age strata, respective prevalence/1,000 in men and women were: <35 years, 0.96 vs. (Fig. 1b) [66] .
In an analysis of the participants of the European Working Party on High Blood Pressure in the Elderly (EWHE), data from 2,295 hypertensives and 2,280 controls were analyzed with regard to diuretic use and the incidence of physician-diagnosed gout during follow-up [67] . The incidence of gout was higher for hypertensives on diuretics than for hypertensives not on diuretics, and higher for both than for controls-for men (10 vs. 6.29 vs. 1.6/1,000 patient years) and women (1.16 vs. 0.69 vs. 0.53/1,000 patient years) (Fig. 1c) . As was clearly evident, the incidence of gout was higher in men than in women [67] . In a small study, the onset of gout in women was a mean of seven years later than in men [68] .
In the recent study that reported NHANES data from 2007-2008, prevalence of gout in men was 5.9 % (95 % CI: 4.7, 7.1) and in women was 2.0 % (95 % CI: 1.5, 2.5) [62] . Mean serum urate was 6.14 (95 % CI: 6.06, 6.23) mg/dl in men and 4.87 (95 % CI: 4.79, 4.94) mg/dl in women. Hyperuricemia, defined as serum urate >7 mg/dl was noted in 21.2 % of men (95 % CI: 18.9, 23.5) and 5.7 % of women (95 % CI: 4.4, 6.9) [62] .
In summary, these data indicate that women have far lower prevalence of gout compared with men. The gender difference gets smaller with increasing age, but men still far outnumber women with gout, even among the elderly. 
Gender Differences in Clinical and Genetic Risk Factors for Gout
In a population-based study, 34,036 people in the Nagano province in Japan were studied for hyperuricemia [69] , the underlying biochemical abnormality in gout; 15,712 were males and 18,324 were females. The study showed that gender was related to serum urate levels across all age strata. Men had a mean serum urate of 5.82 mg/dl (standard deviation [SD], 1.14 mg/dl), and the women 4.33 mg/dl (SD, 0.91 mg/dl) [69] . The gender difference in serum urate decreased with increasing age, such that 15-19-year-old men and women had serum urate levels of 6.1 and 4.6 mg/ dl, respectively, whereas in the 70+ age group serum urate levels were 5.8 and 5.0, respectively.
In a small study of onset of gout in women versus men, there were no differences between women and men regarding multiple known (and potential) risk factors for gout including systemic hypertension, diabetes mellitus, hyperlipidemia, chronic renal failure, ischemic heart disease, or heavy alcohol consumption [68] .
In another study of 132,556 individuals ≥18 years enrolled in Taiwan's National Health Insurance, 1,606 subjects (1,341 men and 265 women) developed incident gout. Hyperuricemia (sUA≥7.7 mg/dL for men or ≥6.6 mg/dL for women) was associated with a hazard ratio of 9.65 (95 % CI, 8.53-10.9) for gout in men and 9.28 (95 % CI, 7.00-12.3) in women [70] . The association of risk factors with incident gout was similar in women and men: hypertension, obesity, and hyperlipidemia were significantly associated, with respective hazard ratios of 1.32 In the study comparing NHANES cohorts of 1988-1994 and 2007-2010, analysis of the association of obesity with the risk of prevalent gout was also performed by gender [61••] . The association of obesity, defined as BMI >30 kg/m 2 , with the risk of prevalent gout seemed similar in men and women. Obesity was associated with a 2.3-times higher risk of prevalent gout in men and a 2.5-times higher risk in women, in a model adjusted for race, age, and race. In a model that also adjusted for hypertension, glomerular filtration rate, total cholesterol, low and high-density lipoprotein, and diabetes, the risk was 1.7 times in men and 1.9 times in women. Thus, no major differences in risk of prevalent gout as a result of obesity were seen for men and women in the US.
In a genomic analysis of the German MI (myocardial infarction) family study, 1,563 unrelated individuals were studied [71] . This included 683 individuals with gout (n0 480 males, n0203 females) and unrelated subjects who neither had any indication of gout nor were medicated with urate-lowering therapy, including uricosuric agents at any time during follow-up (n0871 males, n0692 females; controls). The study confirmed the association with gout of three single-nucleotide polymorphisms (SNPs) in two established genes, namely SLC2A9 (rs734553 and rs6855911) and ABCG2 (rs2231142), for the overall sample. In separate analysis, the authors found an association of both SLC2A9 SNPs (s734553 and rs6855911) with gout both for females and males whereas ABCG2 SNP rs2231142 was significantly associated with gout for males only. Thus, this study indicates that specific genetic risk factors for gout may vary by gender [71] .
These studies indicate that several clinical and genetic risk factors for gout have similar effects on patients, irrespective of gender. The risk imparted by common risk factors for gout, including hypertension, obesity and renal failure, did not differ much by gender. Similar genetic polymorphisms were associated with gout for both males and females.
Disparity in Risk of Adverse Effects
Racial and/or Ethnic Differences
Very few studies have explored whether adverse effects of medications used for the treatment of gout differ by race and/or ethnicity.
One study examined the genetic markers for severe cutaneous adverse reactions (SCARs) in Koreans [72] . Human leukocyte antigen (HLA) class I alleles of 25 cases of allopurinol-induced SCARs (20 cases of drug-induced hypersensitivity syndrome and five cases of Stevens-Johnson syndrome and/or toxic epidermal necrolysis) and 57 patients tolerant to allopurinol were genotyped [72] . It was found that B*5801 (92.0 vs. 10.5 %, P < 0.0001, OR 097.8), Cw*0302 (92.0 vs. 12.3 %, P <0.0001, OR082.1), and A*3303 (88.0 vs. 26.3 %, P<0.0001, OR020.5) were significantly higher for SCARs patients than for tolerant controls. In contrast, A*0201 was not found in SCARs patients despite relatively high frequency in tolerant controls (0 % vs. 29.8 %). This finding of strong positive association of HLA-B*5801 and negative association of HLA-A*0201 with the risk of allopurinol-induced SCARs in the Korean population is a pioneering finding [72] . In a recent doubleblind randomized controlled trial (RCT) that examined the comparative efficacy and safety of febuxostat 40 mg, febuxostat 80 mg, or allopurinol 300 mg (200 mg for patients with moderate renal impairment) for 2,269 subjects, the authors reported that a lower proportion of AfricanAmericans than Caucasians had liver function test abnormality (ALT elevation by a factor of 2 or higher, 2 % vs. 13 %, respectively) [73] . Incidence of most other common adverse events, including upper respiratory symptoms, diarrhea, musculoskeletal symptoms, etc., was not different by race and/or ethnicity [73] .
We could not find any studies that documented gender differences for adverse effects of gout treatments.
Disparity in Treatment and Receipt of Quality Gout Care
There is no evidence to suggest different pharmacokinetics or pharmacodynamics of urate-lowering therapy by age, gender, or race and/or ethnicity. A recent study that examined the pharmacokinetics, pharmacodynamics, and safety of once-daily oral febuxostat 80 mg for healthy male and female subjects after 7 days found minimal differences between peak concentrations of febuxostat and percentage decrease in serum uric acid 24-h mean concentration in men and women [74] . Similarly, a six-month randomized trial of febuxostat compared with allopurinol for patients with gout showed that the efficacy of febuxostat in reducing serum urate was similar for blacks and whites in all treatment groups, irrespective of renal function [73] . These studies support the notion that aggressive gout therapy should be pursued for all patients, irrespective of age, gender, and race and/or ethnicity.
Racial and/or Ethnic Differences
In a study of 663 US veterans with gout who qualified for testing of at least one quality indicator for gout care, racial and/or ethnic disparities were observed [75] . The cohort had a mean age of 68 years, and a Charlson comorbidity score of 2.5; 99 % were men, and of those with known race and/or ethnicity, 96 % were white. Physician adherence to three quality indicators (QIs) for gout patients was examined:
1. lowering of initial daily allopurinol dose to <300 mg/ day in the presence of renal insufficiency; 2. monitoring of serum urate level at least once during the first 6 months of continued use of a xanthine oxidase inhibitor, for example allopurinol; and 3. monitoring of complete blood cell count and creatine kinase at least every 6 months for patients with renal impairment receiving long-term prophylactic oral colchicine (≥0.5 mg/day for ≥6 months).
In the multivariable-adjusted logistic analysis of predictors of overall physician adherence to all QIs applicable as the outcome, patient race was significantly associated with non-adherence to QIs (P 00.035) [75] . Compared with whites with gout, gout patients of non-white race were more likely to be non-adherent to QIs, with an odds ratio of 1.41 (95 % confidence interval, 0.52-3.84) [75] . This association was independent of age, comorbidity index, utilization characteristics (number of inpatient and outpatient visits, type of physician, most frequently seen physician) and health care access (percent service connection).
In an analysis of 3.9 million outpatient visits with a gout diagnosis in 2002 from the National Ambulatory Medical Care Survey in the US, African-Americans were less likely than Caucasians to receive ULT with allopurinol (OR 0.18; 95 % CI, 0.04-0.78; P00.02) and only 10 % of visits were made by African-Americans vs. 82 % by Caucasians [76] . In another study, African-Americans with gout are twice as likely to be non-adherent with ULT than Caucasian patients (OR 1.86; 95 % CI, 1.52-2.27) [77] .
Gender Differences
Studies have indicated that inappropriate prescribing is more common for women than for men among veterans aged ≥65 years, as judged by the Beers criteria for diagnosisadjusted prevalence of 33 potentially inappropriate medications [38] . We examined whether published studies provide evidence of differences in quality of gout care by gender.
In a UK study of 40 practices with 300,000 people, compared with men with gout prescription of allopurinol was lower for women with gout across all age strata, except for the highest age group: <35 years, 48 In an analysis of data from 1.4 million people in managed care plans in the US, Harrold et al. identified 6,133 patients with diagnosis of gout (4,975 men and 1,158 women) [78] . They found that use of diuretics was almost twofold greater for women than for men, 77 % vs. 40 % (P<0.001). The analysis was adjusted for age, total number of encounters with a gout diagnosis, comorbidities, use of diuretics, and health plan. In the adjusted analysis, compared with men, women were less likely to undergo synovial fluid crystal analysis for diagnosis, less likely to receive allopurinol, and more likely to receive glucocorticoids (OR 0.49 (0.34-0.72), 0.78 (0.67-0.90), and 1.30 (1.12-1.50), respectively). Women with gout were more likely to receive serum urate monitoring within 6 months after starting urate-lowering therapy (OR 1.36, 95 % CI 1.11-1.67).
Knowledge Gaps and Future Research
A recent randomized trial reported similar efficacy and safety of febuxostat for blacks and whites with gout [73] . In fact, fewer blacks compared with whites had liver function test abnormalities while taking febuxostat. Thus, lack of race and/or ethnicity differences in success of gout treatment implies that the quality of gout care should not differ by race and/or ethnicity, as noted in a recent editorial [79] . Although specific risk factors (e.g. diuretics) are more common for women than for men, there is no evidence that treatment responses differ by gender. As discussed above, blacks have higher prevalence of gout than whites. This implies that aggressive treatment of gout is necessary among minorities. Because gout is recognized as a disease mostly affecting men, gout in women may be underrecognized, even in the postmenopausal years.
There are several knowledge gaps related to disparities in gout. For example, it is not known whether the higher risk of gout in blacks compared with whites can be attributed to differences between risk factors (renal disease, heart failure, serum urate level, obesity) or to genetic differences related to polymorphisms in genes that regulate urate production and excretion. Even less is known about the interplay of genetics and environment as it relates to differences in the epidemiology of gout by race and/or ethnicity and gender. This implies that more studies of gout in women and minorities are needed. At the very least, results should be presented by gender and race and/or ethnicity for studies with large samples. In particular, RCTs should provide exploratory subgroup analyses by gender and race and/or ethnicity to reveal any differences in outcomes by these factors. Very few studies have examined different aspects of quality of gout care. As health care in the US increasingly changes to electronic health record-based systems, more sources of data will be available for examination of aspects of quality of care, for example those related to safety and efficacy, among patients with gout.
Conclusions
In conclusion, recent interest in developing new gout therapeutics has also re-energized clinical research in gout. The association of gout with cardiac outcomes is yet another reason to justify the extra attention to the optimum control of gout. Racial and/or ethnic minorities may share a higher burden of gout, because of higher prevalence of comorbidities (hypertension, obesity, renal failure, etc.), the use of predisposing medications for example diuretics, and delay in diagnosis and/or treatment. Delay in diagnosis of gout may be greater for women, because the disease is maledominant. More research is needed to provide data for women and for racial and/or ethnic minorities with gout, so that we can learn about similar and different (if any) demographic factors. Although knowing these differences is important, appropriate treatment of gout for all patients, irrespective of gender and race and/or ethnicity, is, perhaps, the most relevant and effective approach.
